2King H, Aubert RE, Herman H. Global burden of diabetes, 1995 - 2025, prevalence, numerical estimates, and projections. Diabetes Care,1998,21 (9) : 1414.
3Qi MY, Xia HJ, Dai DZ, et al. A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac nsufficiency attributed to up - regulation of the expression of FKBP12.6, SERCA2a and PLB in rats. J Cardiovasc Pharmacol,2006 ,47 ( 6 ) : 729.
4北川勋.ゴマノハゲサ科植物成分的研究.Cent J Med,1971,271:721.
5Gumey AM, Howarth FC. Effects of streptozotocin - induced diabetes on the pharmacology of rat conduit and resistance intrapulmonary ar- teries. Cardiovasc Diabeto1,2009,21 ( 8 ) :4.
6Su J, Lucchesi PA, Gonzalez - Villalobos RA, et al. Role of advanced glycation end products with oxidative stress in resistance artery dys- function in type 2 diabetic mice. Arterioscler Thromb Vasc Biol,2008, 28(8) :1432.
7Wong WT, Wong SL, Tian XY, et al. Endothelial dysfunction: the common consequence in diabetes and hypertension. J Cardiovasc Pharmacol, 2010,55 ( 4 ) : 300.
8Xue M, Qian Q, Adaikalakoteswari A ,et al. Activation of NF -E2 - related factor - 2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes, 2008,57(10) :2809.
9Piechota A, Polaflczyk A, Goraca A. Role of endothelin - 1 receptor blockers on hemodynamic parameters and oxidative stress. Pharmacol Rep,2010,62( 1 ) : 28.
10Sun H, Zhong M, Miao Y, et al. Impaired elastic properties of the a- orta in fat - fed, streptozotocin - treated rats. Vascular remodeling in diabetic arteries. Cardiology, 2009,114 ( 2 ) : 107.
